NervGen Pharma Corp.
NGENF
$4.43
$0.204.78%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.56M | 8.37M | 7.26M | 6.73M | 6.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.22M | 19.04M | 18.75M | 18.23M | 16.95M |
| Operating Income | -18.22M | -19.04M | -18.75M | -18.23M | -16.95M |
| Income Before Tax | -18.50M | -19.36M | -18.50M | -17.49M | -17.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.50 | -19.36 | -18.50 | -17.49 | -17.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.50M | -19.36M | -18.50M | -17.49M | -17.67M |
| EBIT | -18.22M | -19.04M | -18.75M | -18.23M | -16.95M |
| EBITDA | -18.18M | -19.00M | -18.71M | -18.17M | -16.89M |
| EPS Basic | -0.26 | -0.27 | -0.26 | -0.25 | -0.27 |
| Normalized Basic EPS | -0.16 | -0.17 | -0.16 | -0.16 | -0.17 |
| EPS Diluted | -0.26 | -0.27 | -0.26 | -0.25 | -0.27 |
| Normalized Diluted EPS | -0.16 | -0.17 | -0.16 | -0.16 | -0.17 |
| Average Basic Shares Outstanding | 285.78M | 282.68M | 280.68M | 270.22M | 259.79M |
| Average Diluted Shares Outstanding | 285.78M | 282.68M | 280.68M | 270.22M | 259.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |